IEEPA Tariff Refunds for Chemical and Pharmaceutical Importers

Chemical and pharmaceutical importers face a paradox in the IEEPA refund landscape: the industry’s complex HTS classifications mean many companies underestimate their exposure, while the high per-shipment values mean the actual refund amounts are often larger than expected. If you import active pharmaceutical ingredients, specialty chemicals, intermediates, or industrial chemicals from China, your IEEPA refund claim may be one of the largest line items on your balance sheet this year.

The Supreme Court’s 6-3 ruling in Learning Resources, Inc. v. Trump on February 20, 2026, declared all IEEPA tariffs unconstitutional. The CIT’s March 4 order directed CBP to process refunds. For chemical and pharmaceutical importers, the combination of China-source dependence (particularly for APIs and intermediates), high compliance standards, and complex classification creates both a significant refund opportunity and a documentation challenge.

This guide covers the specific HTS codes, classification complexities, FDA/EPA regulatory overlaps, and recovery strategies for the chemical and pharmaceutical sector.

Which Chemical and Pharmaceutical Products Qualify

The chemical and pharmaceutical sectors cover an enormous range of HTS codes across more than a dozen chapters. Unlike consumer goods where classification is relatively straightforward, chemical products are classified based on molecular structure, purity, function, and form — all of which affect the applicable tariff rate.

Key HTS Codes for Chemical and Pharmaceutical Importers

NES = Not Elsewhere Specified. Chapter 38 is a catch-all for chemical products that don’t fit neatly into earlier chapters, and it contains many high-value specialty chemical products that are frequently imported from China.

The API Dependency Problem

China supplies an estimated 80% of the active pharmaceutical ingredients used in U.S. drug manufacturing. This isn’t just a trade statistic — it’s a national security concern that was part of the stated rationale for IEEPA tariffs in the first place. Ironically, the tariffs intended to address supply chain dependence on China ended up imposing massive costs on the very companies trying to maintain domestic pharmaceutical production.

Common APIs imported from China and subject to IEEPA tariffs include:

• Acetaminophen (paracetamol) — the most widely used analgesic
• Ibuprofen — NSAID bulk drug substance
• Metformin — diabetes medication API
• Amoxicillin — antibiotic API
• Atorvastatin — cholesterol medication API
• Losartan — blood pressure medication API
• Omeprazole — proton pump inhibitor API
• Amlodipine — cardiovascular API
• Vitamins C, D, E, B12 — bulk vitamin ingredients
• Heparin — anticoagulant precursor

Each of these may be classified under different HTS codes depending on purity, form (powder vs. granular vs. solution), and whether it’s imported as a bulk substance or in dosage form. This classification complexity is why pharmaceutical companies often underestimate their IEEPA exposure — the duties are spread across dozens of HTS codes and may not be immediately recognizable as related products.

Why Pharma Companies Underestimate Their Exposure

There are three structural reasons chemical and pharmaceutical importers tend to underestimate their IEEPA refund eligibility:

1. Multi-Code Classification

A single drug product’s supply chain can involve APIs classified under Chapter 29 (organic chemicals), excipients classified under Chapter 35 (albuminoidal substances), packaging components classified under Chapter 39 (plastics), and the finished dosage form classified under Chapter 30 (pharmaceutical products). Each has its own HTS code, its own IEEPA rate, and its own entry. Companies that track only finished product imports may miss the larger exposure from upstream ingredient imports.

2. Procurement Decoupling

In many pharmaceutical companies, API procurement is handled by a different team than finished goods importing. The supply chain team may not be aware of what the trade compliance team is tracking, and vice versa. When the CFO asks “what’s our IEEPA tariff exposure?” the answer often comes back incomplete because nobody has aggregated across all procurement channels.

3. Intermediates and Precursors

China doesn’t just supply finished APIs — it supplies the chemical intermediates and precursors used to manufacture APIs in India, Europe, and other countries. If your company imports intermediates from China for domestic synthesis, those intermediate imports were subject to IEEPA tariffs. They may be classified under obscure HTS headings that don’t immediately read as “pharmaceutical” but are nonetheless part of your pharma supply chain.

The takeaway: your actual IEEPA exposure is almost certainly larger than your initial estimate. A comprehensive review of all entries across all HTS codes and all brokers is essential.

Get your free Impact Assessment →

Estimating Your Chemical and Pharmaceutical Refund

Chemical and pharmaceutical imports tend to have high per-entry values, particularly for APIs and specialty chemicals. Even relatively small import volumes translate to significant IEEPA duties.

For a generic pharmaceutical manufacturer importing $20 million annually in APIs and intermediates from China at an average IEEPA rate of 25%, the 12-month refund is approximately $5 million.

The Margin Recovery Angle

Pharmaceutical margins vary dramatically by segment:

• Generic manufacturers: 5-15% net margins. IEEPA refund can equal 2-5 years of profit.
• Specialty pharma: 15-30% net margins. IEEPA refund represents significant but less dramatic recovery.
• Chemical distributors: 3-8% net margins. IEEPA refund is transformational.
• Branded pharma: Higher margins, but often the largest absolute import volumes from China.

For the generic pharma segment especially, the IEEPA refund can be the difference between a profitable year and a loss year. These companies couldn’t pass through tariff costs to customers because drug prices are set by contracts with GPOs, PBMs, and government payers. They absorbed the full cost — and now they can recover it.

Documentation Requirements for Chemical and Pharmaceutical Importers

The chemical and pharmaceutical sectors’ high regulatory compliance standards are actually an advantage for refund documentation. Companies that maintain FDA Drug Master Files, EPA TSCA submissions, and GMP batch records already have much of the traceability needed.

Required Documentation

From your customs broker:

• ES-003 reports from ACE for the full IEEPA period
• Entry summaries (CBP Form 7501) for all qualifying entries
• Liquidation status per entry
• HTS line-item detail showing 9903.01 or 9903.02 headings

From your internal records:

• Purchase orders for APIs, intermediates, and chemical raw materials
• Commercial invoices with product specifications (CAS numbers, purity, form)
• Certificates of Analysis (CoAs) from suppliers
• Bills of lading
• Import permits and FDA prior notice filings
• Proof of duty payments

Sector-specific documentation:

• FDA Drug Master File references (for API imports)
• EPA TSCA declarations (for industrial chemicals)
• DEA import permits (for controlled substance precursors)
• GMP batch records linking imported APIs to finished products

Classification Verification

Chemical classification is one of the most technical areas of HTS practice. Misclassification — either by your broker or by CBP on examination — can change your IEEPA rate or even whether IEEPA tariffs applied. Before filing your refund, verify:

• Purity thresholds. Some HTS codes apply only to products above certain purity levels. A chemical at 99% purity may be classified differently than the same compound at 90% purity.
• Form and concentration. Bulk powder, solution, and diluted preparations may have different HTS codes even for the same chemical substance.
• Single compound vs. mixture. Pure compounds (Chapter 28/29) are classified differently than mixtures and preparations (Chapter 38). If your imports include both, they’ll have different HTS codes and potentially different IEEPA rates.

Ensure your HTS codes are accurate before filing. An incorrect classification that reduces your IEEPA refund is money left on the table. An incorrect classification that inflates your refund will result in a rejected claim.

Regulatory Overlap: FDA, EPA, and CBP

Chemical and pharmaceutical importers operate under multiple regulatory agencies, each with its own import requirements. Here’s how they interact with the IEEPA refund:

FDA

FDA-regulated imports (drugs, biologics, medical devices, food additives) undergo FDA review in addition to CBP processing. FDA holds, detentions, or Import Alerts do not affect IEEPA refund eligibility for entries that were ultimately released into U.S. commerce. If an import was refused by FDA and re-exported, no IEEPA duties should have been assessed (or they would have been refunded through the standard process).

EPA (TSCA)

Industrial chemicals must comply with the Toxic Substances Control Act. TSCA certification is required at entry. TSCA compliance issues don’t affect IEEPA refund eligibility — they’re a separate regulatory requirement. However, if a TSCA-non-compliant shipment was denied entry, the same logic as FDA refusals applies.

DEA

Controlled substance precursors require DEA import permits. These imports were subject to IEEPA tariffs like any other chemical import from designated countries. The additional regulatory layer doesn’t change tariff treatment.

The bottom line: regulatory compliance issues under FDA, EPA, or DEA are separate from your IEEPA refund eligibility. As long as the goods entered U.S. commerce and IEEPA duties were paid, the entry qualifies for a refund.

Which Recovery Path Works Best for Chemical and Pharmaceutical Importers

The four recovery paths apply to chemicals and pharma with specific industry considerations.

Recommended Strategy

Step 1 — Comprehensive HTS audit. Before filing anything, verify that you’ve identified all IEEPA-subject entries across all HTS codes. Don’t limit your search to the obvious pharmaceutical chapters (28-30) — check Chapters 32-35, 38, 39, and others where upstream ingredients may be classified. A complete picture of your exposure is step one.

Step 2 — Aggregate across all brokers and entry points. If you use different brokers for API imports vs. finished product imports, or different ports of entry for different product lines, your data is fragmented. Consolidate before filing.

Step 3 — Triage by liquidation status. Sort entries into unliquidated (PSC), within 180-day window (protest), and past 180 days (CIT). The 180-day protest window is particularly important for pharmaceutical companies with regular monthly API shipments — you may have entries approaching deadline every month.

Step 4 — File PSCs and protests. For unliquidated entries, file post-summary corrections. For entries within the protest window, file protests immediately. The 7 steps to file your IEEPA tariff refund provides the procedural walkthrough.

Step 5 — Model the time value of your claim. Pharmaceutical companies’ cost of capital and reinvestment opportunities should drive the decision between waiting for CAPE and pursuing immediate capital. For a generic manufacturer with $5 million in refund claims and a 10% WACC, every year of delay costs $500,000 in opportunity cost. The CFO guide to IEEPA recovery provides the analytical framework.

The Supply Chain Security Angle

The IEEPA tariffs on Chinese APIs and chemical intermediates raised fundamental questions about pharmaceutical supply chain security. With the tariffs now invalidated, those questions remain unanswered — but the refund creates an opportunity.

Pharmaceutical companies that used the tariff period to invest in domestic API manufacturing, alternative sourcing from India or Europe, or vertical integration can use the IEEPA refund to offset those diversification costs. Companies that didn’t diversify now have capital to fund supply chain resilience investments.

Either way, the refund represents a rare opportunity to simultaneously recover past costs and invest in future supply chain security. The cost of waiting applies here too — the sooner you have the capital, the sooner you can deploy it.

Chemical and Pharmaceutical FAQ

Are finished dosage form (tablet, capsule) imports eligible, or only bulk APIs?

Both are eligible. Finished dosage forms imported from China under Chapter 30 HTS codes were subject to IEEPA tariffs, as were bulk APIs under Chapters 28 and 29. Each has its own HTS code and IEEPA rate. If you import both, each generates a separate refund claim.

My company imports a chemical that’s classified differently by different brokers. Which classification controls the refund?

The HTS classification on the actual entry summary filed with CBP controls. If different brokers classified the same product differently, the IEEPA duty amount may vary between entries. Your refund is based on the duties actually assessed and paid, not on a theoretical correct classification. However, if you believe a broker misclassified your product and you paid more IEEPA duty than necessary, you can seek both a classification correction and an IEEPA refund.

We import the same API from both China and India. Only the China imports qualify, right?

Correct. India was not subject to IEEPA tariffs. Only imports from IEEPA-designated countries (primarily China, Canada, and Mexico) qualify for refunds. If you import the same product from multiple countries, only the entries from IEEPA-designated origins are eligible. Your ES-003 reports will show country of origin for each entry.

Our API imports are classified under multiple HTS codes depending on form (powder, granular, solution). Do all forms qualify?

Yes, all forms qualify as long as they were subject to IEEPA tariffs. The HTS code may differ based on form, and the IEEPA rate may vary slightly between codes, but all China-origin entries under 9903 headings during the covered period are eligible. The calculate your IEEPA tariff refund amount guide explains how different rates affect your total.

What about pharmaceutical packaging imported from China — vials, blister packs, bottles?

Pharmaceutical packaging materials are classified under their own HTS codes (typically Chapter 39 for plastic, Chapter 70 for glass, Chapter 76 for aluminum). If these were imported from China during the IEEPA period and subject to IEEPA tariffs, they qualify for refunds. Packaging imports are frequently overlooked because they’re managed by a different procurement team than API purchasing. Include them in your analysis — they can represent a meaningful addition to your total claim.

The Bottom Line for Chemical and Pharmaceutical Importers

Chemical and pharmaceutical importers are in a unique position: your sector’s classification complexity means you probably underestimate your IEEPA exposure, while your high per-shipment values mean the actual refund is likely larger than you expect. The combination of multi-code products, fragmented procurement channels, and upstream intermediate imports creates blind spots that a comprehensive entry-level analysis will illuminate.

The regulatory compliance infrastructure you already maintain — FDA filings, TSCA certifications, GMP batch records — gives you a documentation advantage that most industries don’t have. Use it.

Start with a complete picture of your IEEPA exposure across all HTS codes, all brokers, and all product categories. The refund amount will justify the effort.